Ask your doctor how long-acting antibodies can be an option for an additional layer of protection against COVID-19
Response to COVID-19 vaccination may be lower because of certain medical conditions and/or treatments such as:1,2
Receipt of solid-organ and/or bone marrow transplant
Active treatment for solid tumor and hematologic malignancies
Taking immunosuppressive therapies
Advanced or untreated HIV infection
Moderate or severe primary immunodeficiency
Chronic kidney disease or on dialysis
COVID-19=coronavirus disease 2019; HIV=human immunodeficiency virus.
The UAE MOHAP has more information on these here.
The KSA MOH has more information on these here.
In a study of hospitalised COVID-19 patients,
~40%
of patients with week immune system mounted lower response to vaccination.3,4
Layers of protection against COVID-19
Wearing a mask, social distancing, and practicing hand hygiene can be preventative options to help protect you against COVID-19
Vaccination, including boosters, if appropriate
Long-acting antibodies can be used for prevention of COVID-19 on top of vaccines5
 
Vaccines provide the first layer of protection against COVID-19 by creating an immune response. However, for individuals that may not mount an adequate immune response, a long-acting antibody option may provide an additional layer of protection against COVID-19.6,7
Talk to your doctor today about what else you can do to help protect yourself from COVID-19.

References:

  1. Dooling K . Evidence to recommendation framework: an additional dose of mRNA COVID-19 vaccine following a primary series in immunocompromised people. Available at: https://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2021-08-13/02-COVID-Dooling-508.pdf. Accessed August 2022.
  2. Janus N, Vacher LV, Karie S et.al. Vaccination and chronic kidney disease. Nephrol Dial Transplant.2008;23(3):800-807.
  3. Oliver, S MD. Data and clinical considerations for additional doses in immunocompromised people. ACIP Meeting July 22, 2021. Available at: https://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2021-07/07-COVID-Oliver-508.pdf. Accessed August 2022.
  4. Shields A M et al. Outcomes following SARS-CoV-2 infection in patients with primary and secondary immunodeficiency in the UK. Clinical and Experimental Immunology 2022. Available at: https://academic.oup.com/cei/advance-article/doi/10.1093/cei/uxac008/6515671. Accessed August 2022.
  5. FDA News release. Coronavirus (COVID-19) Update: FDA Authorizes New Long-Acting Monoclonal Antibodies for Pre-exposure Prevention of COVID-19 in Certain Individuals. Available at: https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-new-long-acting-monoclonal-antibodies-pre-exposure. Accessed August 2022.
  6. Taylor PC, Adams AC, Hufford MM, de la Torre I, Winthrop K, Gottlieb RL. Neutralizing monoclonal antibodies for treatment of COVID-19. Nat Rev Immunol. 2021;21(6):382-393.
  7. Fact Sheet for Patients, Parents And Caregivers Emergency Use Authorization (EUA) of EVUSHELD™ (tixagevimab co-packaged with cilgavimab) for Coronavirus Disease 2019 (COVID-19).
Legal notice and terms of use Cookie policy Privacy notice Contact us

Disclaimer

The information contained on this website does not represent medical recommendations. If in doubt, consult a doctor.
The notes contained in this website page exclusively represent the opinion of the authors of the articles in reference and not that of AstraZeneca
This is not a platform to promote any product or Health Care Professional (HCP). This is only for patient and HCP education.

Copyrights 2022 AstraZeneca. All rights reserved. Approval Code: Z5-5609
Date of Preparation: August 2022
Date of Expiry: August 2024
For Gulf
For Reporting Adverse events and/or Product Quality Complains:
Website: https://contactazmedical.astrazeneca.com
E-mail: Patientsafety-azgulf@astrazeneca.com
Call AstraZeneca FZ LLC land line: +97143624888.
For Medical information Enquires:
Website: https://contactazmedical.astrazeneca.com
E-mail: gulf-medicalinfo@astrazeneca.com
Call AstraZeneca FZ LLC land line: +97143624888.
AstraZeneca International | Gulf
17th Floor, South Tower, Dubai Science Park,
PO Box 505070, Dubai – UAE
Tel: +971(4)362 4888
Fax: +971(4)362 4898/9
For Saudi
For Medical information please send an email to medinfo-ksa@astrazeneca.com
For AE reporting send email to ksa.ae@astrazeneca.com
ﻓﻲ ﺣﺎﻟﺔ وﺟﻮد أ ي أﻋﺮاض ﺟﺎﻧﺒﯿﺔ ﻟﻸدوﯾﺔ اﻟﺮﺟﺎء اﻟﺘﻮاﺻﻞ ﻣﻊ اﻟﻬﯿﺌﺔ اﻟﻌﺎﻣﺔ ﻟﻠﻐﺬاء واﻟﺪواء ﻋﻦ ﻃﺮﯾﻖ اﻟﺮﻗﻢ اﻟﻤﻮﺣﺪ 19999
Al-Nakhla Tower - Floor 13th Ath Thumamah, Road - Al Sahafa District. 7198 Unit No. 20 Riyadh 13315 – 3642.
Tel: +966 (011) 22 492 00
Fax: +966 (011) 22 492 91
SFDA Approval Code: 9-SFDA-44